X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs PANACEA BIOTECH - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS PANACEA BIOTECH NOVARTIS/
PANACEA BIOTECH
 
P/E (TTM) x 464.6 -5.3 - View Chart
P/BV x 27.0 2.9 940.6% View Chart
Dividend Yield % 1.7 0.0 -  

Financials

 NOVARTIS   PANACEA BIOTECH
EQUITY SHARE DATA
    NOVARTIS
Mar-18
PANACEA BIOTECH
Mar-18
NOVARTIS/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs758364 208.2%   
Low Rs579129 448.5%   
Sales per share (Unadj.) Rs228.496.8 236.0%  
Earnings per share (Unadj.) Rs31.7-12.4 -255.8%  
Cash flow per share (Unadj.) Rs32.8-2.9 -1,148.6%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.150.4 589.6%  
Shares outstanding (eoy) m24.6961.25 40.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.92.5 114.9%   
Avg P/E ratio x21.1-19.9 -106.0%  
P/CF ratio (eoy) x20.4-86.4 -23.6%  
Price / Book Value ratio x2.24.9 46.0%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,50515,101 109.3%   
No. of employees `0000.72.5 27.1%   
Total wages/salary Rs m1,4451,516 95.3%   
Avg. sales/employee Rs Th8,441.32,401.9 351.4%   
Avg. wages/employee Rs Th2,163.6614.2 352.3%   
Avg. net profit/employee Rs Th1,173.1-307.9 -380.9%   
INCOME DATA
Net Sales Rs m5,6395,928 95.1%  
Other income Rs m1,71882 2,087.8%   
Total revenues Rs m7,3576,010 122.4%   
Gross profit Rs m-63845 -7.4%  
Depreciation Rs m25585 4.3%   
Interest Rs m551,006 5.5%   
Profit before tax Rs m1,575-664 -237.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m02 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m79299 802.8%   
Profit after tax Rs m784-760 -103.1%  
Gross profit margin %-1.114.3 -7.8%  
Effective tax rate %50.3-14.9 -338.2%   
Net profit margin %13.9-12.8 -108.4%  
BALANCE SHEET DATA
Current assets Rs m9,5225,603 169.9%   
Current liabilities Rs m3,2966,910 47.7%   
Net working cap to sales %110.4-22.0 -500.8%  
Current ratio x2.90.8 356.2%  
Inventory Days Days37206 17.8%  
Debtors Days Days2884 33.9%  
Net fixed assets Rs m469,941 0.5%   
Share capital Rs m12361 201.3%   
"Free" reserves Rs m7,2133,026 238.4%   
Net worth Rs m7,3363,087 237.7%   
Long term debt Rs m05,707 0.0%   
Total assets Rs m11,10516,076 69.1%  
Interest coverage x29.50.3 8,663.6%   
Debt to equity ratio x01.8 0.0%  
Sales to assets ratio x0.50.4 137.7%   
Return on assets %7.61.5 494.0%  
Return on equity %10.7-24.6 -43.4%  
Return on capital %22.23.9 567.5%  
Exports to sales %024.0 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA1,424 0.0%   
Imports (cif) Rs mNA1,040 0.0%   
Fx inflow Rs m611,600 3.8%   
Fx outflow Rs m3,6301,131 320.8%   
Net fx Rs m-3,570469 -761.8%   
CASH FLOW
From Operations Rs m1,6101,180 136.4%  
From Investments Rs m687553 124.3%  
From Financial Activity Rs m-2,677-1,644 162.9%  
Net Cashflow Rs m-38090 -423.2%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 0.6 333.3%  
FIIs % 1.6 1.3 123.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 23.6 91.1%  
Shareholders   41,647 10,259 406.0%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   IPCA LABS  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Dividend Stocks Amid Volatile Stock Markets; US-China Trade War and More(Podcast)

The market, which has been caught in the grip of the bears, gave a negative yearly return for first time in last eight years.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

7 Stocks to Buy in Today's Difficult Market(The 5 Minute Wrapup)

Aug 5, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

The Perfect Stock in the Rebirth of India(The 5 Minute Wrapup)

Aug 8, 2019

This debt-free, well-managed company is all set to soar.

My Top 3 Dividend Millionaire Stocks(Profit Hunter)

Aug 7, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 16, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS